ReviewJournal of molecular neuroscience : MN2025
Genetics and Epigenetics of Alzheimer's Disease: Understanding Pathogenesis and Exploring Therapeutic Potential.
Review in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticles that target nonamyloid and nontau pathways in Alzheimer's disease.Discover nano · 2026Review
- Quo Vadis translational neuroscience?Translational neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder that affects millions of individuals globally. Despite extensive research efforts, effective treatments for AD remain elusive. AD pathogenesis is driven by a combination of genetic, epigenetic, and environmental factors. However, challenges persist in AD genetic and epigenetic research, including the need for larger and more diverse cohorts, the integration of multi-omic data, and the development of advanced computational and experimental tools. A comprehensive understanding of these factors is crucial for the development of effective treatments and ultimately a cure for this debilitating condition. In this review, we summarize key regulatory pathways involved in AD pathogenesis, emphasizing genetic factors such as the apolipoprotein E (APOE) gene and high-impact genetic mutations in amyloid precursor protein (APP) and presenilin 1 (PSEN1). We also explore significant epigenetic regulators, including DNA methylation, histone deacetylases (HDACs), and microRNAs (miRNAs), which modulate gene expression and contribute to disease progression. Furthermore, we discuss the interplay between genetic and epigenetic factors, highlighting their combined impact on β-amyloid deposition, tau pathology, neuroinflammation, and synaptic dysfunction. Finally, we examine the potential of epigenetic modifications as promising therapeutic targets for AD, due to their reversible nature, and propose future research directions to address current knowledge gaps. This review offers an updated perspective on AD genetics and epigenetics, providing insights into novel avenues for therapeutic intervention.
Indexed as
Identifiers
40447964What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.